Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000594045 | SCV000703060 | uncertain significance | not provided | 2016-10-27 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002469215 | SCV002765938 | uncertain significance | not specified | 2022-11-04 | criteria provided, single submitter | clinical testing | Variant summary: GALC c.500A>G (p.Asn167Ser) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 249508 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.500A>G has been reported in the literature in individuals with low GALC activity via newborn screening, without strong evidence for causality (Orsini_2016). These reports do not provide unequivocal conclusions about association of the variant with Krabbe Disease. The variant was reported as having slightly reduced GALC activity compared to wild-type in COS1 cells (Saavedra-Martiz_2016). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Fulgent Genetics, |
RCV002497254 | SCV002781258 | uncertain significance | Galactosylceramide beta-galactosidase deficiency | 2022-05-16 | criteria provided, single submitter | clinical testing |